Käsmann, L.* et al. Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): Protocol for a prospective longitudinal biomarker study. Transl. Lung Cancer Res. 11, 1503-1509 (2022)